Alexion Pharmaceuticals Inc. (NASDAQ:ALXN)‘s stock had its “buy” rating reissued by research analysts at Cowen and Company in a research note issued on Thursday.

ALXN has been the subject of a number of other reports. Credit Suisse Group AG raised shares of Alexion Pharmaceuticals from a “neutral” rating to an “outperform” rating in a research note on Saturday, July 9th. Zacks Investment Research raised shares of Alexion Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, May 30th. Royal Bank Of Canada assumed coverage on shares of Alexion Pharmaceuticals in a research note on Tuesday, July 12th. They issued an “outperform” rating and a $188.00 target price for the company. Vetr raised shares of Alexion Pharmaceuticals from a “buy” rating to a “strong-buy” rating and set a $171.50 target price for the company in a research note on Wednesday, June 8th. Finally, Citigroup Inc. reaffirmed a “hold” rating on shares of Alexion Pharmaceuticals in a research note on Tuesday, June 7th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating, thirteen have given a buy rating and two have assigned a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $182.85.

Analyst Recommendations for Alexion Pharmaceuticals (NASDAQ:ALXN)

Alexion Pharmaceuticals (NASDAQ:ALXN) traded up 0.74% during midday trading on Thursday, reaching $131.32. The company had a trading volume of 348,351 shares. The stock’s 50 day moving average price is $131.16 and its 200-day moving average price is $135.82. The firm has a market capitalization of $29.45 billion, a P/E ratio of 329.95 and a beta of 1.08. Alexion Pharmaceuticals has a one year low of $110.56 and a one year high of $193.45.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/22/alexion-pharmaceuticals-alxn-buy-rating-reaffirmed-at-cowen-and-company.html

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its earnings results on Thursday, July 28th. The biopharmaceutical company reported $1.13 earnings per share for the quarter, missing the Zacks’ consensus estimate of $1.17 by $0.04. The company earned $753 million during the quarter, compared to analyst estimates of $743.18 million. Alexion Pharmaceuticals had a return on equity of 10.02% and a net margin of 3.19%. Alexion Pharmaceuticals’s revenue for the quarter was up 18.4% on a year-over-year basis. During the same period in the previous year, the company posted $1.44 earnings per share. On average, equities research analysts anticipate that Alexion Pharmaceuticals will post $4.65 earnings per share for the current year.

In other Alexion Pharmaceuticals news, Director Alvin S. Parven sold 15,000 shares of the firm’s stock in a transaction that occurred on Monday, August 22nd. The shares were sold at an average price of $136.53, for a total value of $2,047,950.00. Following the sale, the director now owns 6,373 shares in the company, valued at $870,105.69. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Vikas Sinha sold 277 shares of the firm’s stock in a transaction that occurred on Monday, August 8th. The shares were sold at an average price of $137.14, for a total transaction of $37,987.78. Following the completion of the sale, the chief financial officer now owns 178,463 shares in the company, valued at approximately $24,474,415.82. The disclosure for this sale can be found here. Corporate insiders own 4.41% of the company’s stock.

A number of hedge funds have recently modified their holdings of ALXN. Evercore Wealth Management LLC raised its stake in shares of Alexion Pharmaceuticals by 5.0% in the second quarter. Evercore Wealth Management LLC now owns 1,735 shares of the biopharmaceutical company’s stock worth $203,000 after buying an additional 83 shares in the last quarter. Kentucky Retirement Systems Insurance Trust Fund bought a new stake in shares of Alexion Pharmaceuticals during the second quarter worth $1,056,000. Kentucky Retirement Systems bought a new stake in shares of Alexion Pharmaceuticals during the second quarter worth $2,224,000. Mason Street Advisors LLC bought a new stake in shares of Alexion Pharmaceuticals during the second quarter worth $3,523,000. Finally, Cowen Group Inc. raised its stake in shares of Alexion Pharmaceuticals by 36.4% in the second quarter. Cowen Group Inc. now owns 4,500 shares of the biopharmaceutical company’s stock worth $525,000 after buying an additional 1,200 shares in the last quarter. Hedge funds and other institutional investors own 96.34% of the company’s stock.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. The Company operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company’s marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).

5 Day Chart for NASDAQ:ALXN

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.